Remedy Pharmaceuticals
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
233 Broadway Rm 1750, New York, New York...Phone Number
(212) 586-2226Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Remedy Pharmaceuticals
Remedy Pharmaceuticals is dedicated to improving the lives of individuals affected by central nervous system (CNS) diseases and injuries, particularly through their innovative stroke treatment, CIRARA. The company focuses on addressing the challenges of ischemic strokes, especially Large Hemispheric Infarctions (LHI), by targeting the SUR1-TRPM4 channel to prevent life-threatening cerebral edema. With promising clinical trial results indicating significant improvements in patient outcomes and reduced mortality rates, Remedy is preparing for a pivotal Phase 3 trial to further validate CIRARA's efficacy. Their commitment to advancing stroke treatment aims to provide hope and better quality of life for patients and their families.Explore more
Remedy Pharmaceuticals Org Chart
AT
Clinical Operations Vice President, Regulator...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Remedy Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Remedy Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Remedy Pharmaceuticals recently announced quarterly report
Click to see if Remedy Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Remedy Pharmaceuticals
Remedy Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Remedy Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Check out if Remedy Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Remedy Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Remedy Pharmaceuticals as Masked Content
Find 3 more new buyers
Compare Similar Companies to Remedy Pharmaceuticals
Compare insights from companies similar to Remedy Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Remedy Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Remedy Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Remedy Pharmaceuticals.
Remedy Pharmaceuticals financials insights
Gather financial insights about Remedy Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series B
$1.2M
2020
Debt
$150K
2021
Debt
$161K
Remedy Pharmaceuticals Tech Stack
A closer look at the technologies used by Remedy Pharmaceuticals
Most Recent Scoops
Funding
Remedy Pharmaceuticals has received an SBA PPP loan in the amount of $161,055 from JPMorgan Chase resulting in the retention of 7 jobs.
Funding
Remedy Pharmaceuticals has received an SBA PPP loan for $150,000-350,000 from JPMorgan Chase Bank, supporting the retention of 7 jobs.
Funding
Remedy Pharmaceuticals recently secured $3 million in an unknown Series funding round.
Funding
Funding
Remedy Pharmaceuticals recently secured $9 million in an unknown Series funding round. Vertical GP-5 led the investment.
Funding
Funding
Funding
Remedy Pharmaceuticals News & Media
Remedy Pharmaceuticals to Showcase Groundbreaking Phase 3 CHARM Study Data on CIRARA® at International Stroke Conference 2025
NEW YORK, Jan. 29, 2025 /PRNewswire/ -- Remedy Pharmaceuticals, the developer of CIRARA (intravenous glyburide) for the treatment of Large Hemispheric Infarction (LHI) today announced three speaker presentations of efficacy data from both the Phase 2 GAMES-RP and Phase 3 CHARM study on...Remedy Pharmaceuticals Receives FDA Guidance to Advance CIRARA for Treatment of Severe Stroke
NEW YORK, Nov. 19, 2024 /PRNewswire/ -- Remedy Pharmaceuticals, a leader in stroke drug development, announced today that a Type C meeting held with the U.S. Food and Drug Administration (FDA) on October 16, 2024, provided valuable feedback on the design of a Phase 3 trial of its...Remedy Pharmaceuticals Announces FDA Orphan Drug Designation Granted for the Treatment of Large Territory Acute Ischemic Stroke with CIRARA
NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Remedy Pharmaceuticals, a pioneer in stroke drug development, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation for CIRARA for the treatment of "large...Remedy Pharmaceuticals' Phase 3 Trial in Large Lesion Stroke Patients Demonstrates Statistically Significant Effect at One Year
NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Remedy Pharmaceuticals today announced additional promising data from the Phase 3 CHARM clinical trial of CIRARA (IV glyburide) in patients with Large Hemispheric Infarction (LHI), the most serious form of ischemic stroke, characterized by...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Remedy Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Remedy Pharmaceuticals is dedicated to improving the lives of individuals affected by central nervous system (CNS) diseases and injuries, particularly through their innovative stroke treatment, CIRARA. The company focuses on addressing the challenges of ischemic strokes, especially Large Hemispheric Infarctions (LHI), by targeting the SUR1-TRPM4 ch... Read More
